Safety and efficacy of azacitidine in myelodysplastic syndromes

被引：25

作者：

Vigil, Carlos E. ^{[1
]}

Martin-Santos, Taida ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2010年 / 4卷

关键词：

Azacitidine; MDS; hypomethylating agents; MYELOID-LEUKEMIA; VALPROIC ACID; 5-AZACYTIDINE; TRANSPLANTATION; EXPRESSION; 5-AZA-2'-DEOXYCYTIDINE; METHYLATION; COMBINATION; ANTIGENS; CANCER;

D O I：

10.2147/DDDT.S3143

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Purpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed. Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.

引用

页码：221 / 229

页数：9

共 50 条

[31] Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
Fraison, Jean-Baptiste
Mekinian, Arsene
Grignano, Eric
Kahn, Jean-Emmanuel
Arlet, Jean-Benoit
Decaux, Olivier
Denis, Guillaume
Buchdahl, Anne-Laure
Omouri, Mohamed
Maigne, Gwenola
Aouba, Achille
Leon, Nathalie
Berthier, Sabine
Liozon, Eric
Park, Sophie
Gardin, Claude
Lortholary, Olivier
Rossignol, Julien
Fenaux, Pierre
Fain, Olivier
Braun, Thorsten
LEUKEMIA RESEARCH, 2016, 43 : 13 - 17
[32] Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
Garcia-Manero, G.
Gore, S. D.
Kambhampati, S.
Scott, B.
Tefferi, A.
Cogle, C. R.
Edenfield, W. J.
Hetzer, J.
Kumar, K.
Laille, E.
Shi, T.
MacBeth, K. J.
Skikne, B.
LEUKEMIA, 2016, 30 (04) : 889 - 896
[33] Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
G Garcia-Manero
S D Gore
S Kambhampati
B Scott
A Tefferi
C R Cogle
W J Edenfield
J Hetzer
K Kumar
E Laille
T Shi
K J MacBeth
B Skikne
Leukemia, 2016, 30 : 889 - 896
[34] Azacitidine: A Review of its Use in the Management of Myelodysplastic Syndromes
Lammers, Philip E.
Cashen, Amanda F.
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1189 - 1197
[35] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
Dinmohamed, A. G.
van Norden, Y.
van de Loosdrecht, A. A.
Jongen-Lavrencic, M.
LEUKEMIA, 2016, 30 (08) : 1795 - +
[36] Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes
Kim, In-Ho
Youn, Jae-Ho
Shin, Seung-Hwan
Yahng, Seung-Ah
Lee, Sung-Eun
Kwon, Jae-Cheol
Lee, Dong-Gun
Park, Kyung-Shin
Choi, Moon-Hyung
Jung, Seung-Eun
Kim, Yoo-Jin
LEUKEMIA RESEARCH, 2012, 36 (07) : E146 - E148
[37] 5′-Azacitidine in myelodysplastic syndromes with inversion of chromosome 3
Breccia, M.
Cannella, L.
Santopietro, M.
Loglisci, G.
Federico, V.
Salaroli, A.
Nanni, M.
Mancini, M.
Alimena, G.
LEUKEMIA, 2011, 25 (04) : 736 - 737
[38] AZACITIDINE IS THE PREPARATION OF CHOICE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES PATIENTS
Dokshina, I. A.
Minaeva, N., V
Pozdeev, N. M.
Fedorovskaya, N. S.
Ovsepyan, V. A.
Rylov, A., V
Paramonov, I., V
GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2017, 62 (02): : 60 - 64
[39] An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes
Pleyer, Lisa
Sekeres, Mikkael A.
LANCET HAEMATOLOGY, 2022, 9 (10): : E714 - E716
[40] Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia
Scott, Lesley J.
DRUGS, 2016, 76 (08) : 889 - 900

← 1 2 3 4 5 →